Benzoyl peroxide/clindamycin low dose - Ortho Dermatologics

Drug Profile

Benzoyl peroxide/clindamycin low dose - Ortho Dermatologics

Alternative Names: Acanya Gel; BenzaClin Topical Gel; Clin-BPO 2.5%; Clindamycin phosphate 1.2% and benzoyl peroxide 2.5%; Clindamycin phosphate 1.2% and benzoyl peroxide 3.75%; Clindamycin/benzoyl peroxide - Ortho Dermatologics; IDP-110; ONEXTON Gel

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arcutis Pharmaceuticals
  • Developer Ortho Dermatologics
  • Class Antiacnes; Antibacterials; Benzoic acids; Lincosamides; Oxidants; Small molecules
  • Mechanism of Action Keratinocyte inhibitors; Protein 50S ribosomal subunit inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 22 Sep 2015 Generic equivalent available in USA for Acne vulgaris
  • 25 Nov 2014 The US FDA approves benzoyl peroxide/clindamycin gel 3.75%/1.2% for Acne vulgaris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top